We are live on ! Find out more
SRNE

Sorrento Therapeutics, Inc.

Delisted

SRNE was delisted on the 22nd of February, 2023.

234 hedge funds and large institutions have $433M invested in Sorrento Therapeutics, Inc. in 2021 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 72 increasing their positions, 58 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $48.9M | Put options by funds: $24.9M

43% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 37

24% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 58

6% more funds holding

Funds holding: 220234 (+14)

34% less capital invested

Capital invested by funds: $658M → $433M (-$225M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
234
Holders Change
+14
Holders Change %
+6.36%
% of All Funds
3.59%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
53
Increased
72
Reduced
58
Closed
37
Calls
$48.9M
Puts
$24.9M
Net Calls
+$24M
Net Calls Change
-$12.7M

SRNE Hedge Fund Activity: Q4 2021 in Review

234 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q4 2021, worth a combined $433M — down 34% from $658M a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new SRNE positions and 37 closed out — a net gain of 16 holders — while 72 added to existing stakes and 58 trimmed.

The largest buyer was State Street, adding an estimated $14.3M. The largest seller was D.E. Shaw & Co, cutting an estimated $3.14M.

  • 234 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q4 2021, up from 220 in Q3 2021.
  • Funds reported $433M of Sorrento Therapeutics, Inc. stock for Q4 2021, down 34% quarter-over-quarter.
  • 53 funds opened new Sorrento Therapeutics, Inc. positions in Q4 2021 and 37 closed out, a net change of +16 holders.
  • The largest Sorrento Therapeutics, Inc. buyer in Q4 2021 was State Street, an estimated $14.3M added.
  • The largest Sorrento Therapeutics, Inc. seller in Q4 2021 was D.E. Shaw & Co, an estimated $3.14M sold.

Based on aggregated 13F filings for Q4 2021.